What is Terumo Corporation (TRUMY)?

Terumo Corporation (TRUMY) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of TRUMY?

The current price of TRUMY is $15.14. Prices are updated in real time on Stocks360.

What is TRUMY's price-to-earnings (PE) ratio?

TRUMY's trailing twelve-month PE ratio is 21.57, based on current price and earnings per share data available on Stocks360.

What is TRUMY's market capitalization?

TRUMY's market capitalization is $22,333,041,449.00, placing it in the large-cap tier.

Does TRUMY pay a dividend?

Yes. TRUMY has a trailing twelve-month dividend yield of 0.01%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Terumo Corporation (TRUMY)

Stock analysis · OTC · Healthcare · Medical - Devices

$15.14

Market Cap

$22.33B

PE (TTM)

21.57

EPS (TTM)

N/A

Dividend Yield

1.37%

Beta

0.23

Day Range

$15.11 – $15.26

52-wk Range

$12.08 – $16.99

Avg Volume

N/A

Volume

2.47K

Terumo Corporation (TRUMY) is a publicly traded company in the Healthcare sector. Latest price: $15.14. Market cap $22.33B. Trailing PE 21.57. Dividend yield 1.37%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $16.14 2026-10-30 · $15.14 (-6.20%)

Earnings

Most Recent

Aug 7, 2026

EPS $0.30 vs est. $0.17

Beat by $0.13

Next Earnings

Nov 12, 2026

EPS estimate $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Terumo Corporation

Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular division provides critical devices for cardiovascular and cerebrovascular interventions, including angiographic guidewires, various catheters (angiographic, PTCA balloon, imaging), introducer sheaths, vascular closure devices, coronary and self-expanding peripheral stents, and intravascular ultrasound systems; it also develops specialized tools for cerebral aneurysm treatment like coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke, further supplying oxygenators, cardio-pulmonary bypass systems, and artificial vascular and stent grafts. The Medical Care Solutions segment offers a comprehensive range of general medical products such as syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritional products, an…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	21.57×
P/S (TTM)	3.00×
P/B	2.13×
PEG	0.68×
P/FCF (TTM)	18.49×
EV / EBITDA	12.26×
EV / Sales	3.06×
Earnings Yield	4.64%
Free Cash Flow Yield	5.41%
Dividend Yield	1.37%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.62T
Revenue (TTM)	$1.18T
Net Income (TTM)	$164.50B
Free Cash Flow (TTM)	$174.88B
Net Debt	$74.83B
Working Capital	$493.33B
Gross Margin	53.03%
Operating Margin	16.90%
Net Margin	13.90%
Return on Equity	10.60%
Return on Invested Capital	7.21%